3 / 13
Page 29
Interventional Cardiology Journal
ISSN: 2471-8157
2
n d
E d i t i o n o f E u r o S c i C o n C o n g r e s s o n
Heart Disease and
Interventional Cardiology
F e b r u a r y 2 5 - 2 6 , 2 0 1 9
P a r i s , F r a n c e
Heart and World Cardiology 2019
F
or cell therapy on myocardial infarction, many kinds of cells have been
studied. In our experience since 2001, the implant of mesenchymal stem
cells CD34+ obtained from peripheral blood showed inconsistent improvement
in the contractile function of infarcted myocardial tissue, but better survival
in long term. For improved cell therapy, in 2014 we characterized the kind of
cells that were mobilized to peripheral blood in patients with acute myocardial
infarction, which were identified as a response of bone marrow to myocardial
insult. In 2015, we began a clinical trial with CXCR4-stem cells and specific
cells markers in patients with old myocardial infarction and reduced LVFE.
Cells with specific markers were separated with immune-magnetic autoMACS
Pro Separator machine and implanted on infarcted myocardial tissue guided
by epicardial ultrasound.
Results:
To the date we have evaluated 15 patients followed by 12 months,
we observed a standardized respond in myocardial perfusion and LVEF at six
months, as well as improvement in their functional class from NYHA III to I in
all patients.
Conclusion:
CXCR4-stem cells with specific cells markers improve the
myocardial perfusion and contraction of left ventricle in patients with old
myocardial infarction in a standardized way.
Biography
José Luis Aceves Chimal has completed his MSc, PhD from
Universidad Nacional Autónoma de México, and Postdoctoral
studies from National Nutrition Institute Salvador Subiran.
He is a Cardiovascular Surgeon and Researcher in National
Medical Center 20 de Noviembre ISSSTE in México City. He
has published more than 20 papers in reputed journals and has
been serving as an Editorial Board Member of repute.
acevesch@hotmail.esCXCR4-stem cell therapy in old myocardial infarction
José Luis Aceves Chimal
1
, Rafael Vilchis Lópe
1
, Virna Poveda
Samaniego
1
, Paul Mondragón Terán
1
, Mario Marroquin
1
,
Daniel Santillan
1
, Mario Tellez
1
, Miriam Marmolejo
1
, Fernando
Rodriguez
1
and Luis Felipe Montaño Estrada
2
1
National Medical Center 20 de Noviembre ISSSTE, México
2
Universidad Nacional Autónoma de México, México
José Luis Aceves Chimal et al., Interv Cardiol J 2019, Volume: 5
DOI: 10.21767/2471-8157-C1-005